S&P Futures
4,171.00 -20.50 (-0.49%) Dow Futures
34,111.00 +14.00 (+0.04%) Nasdaq Futures
12,664.00 -182.75 (-1.42%) Russell 2000 Futures
2,007.50 -0.40 (-0.02%) Crude Oil
75.64 -0.24 (-0.32%) Gold
1,929.70 -1.10 (-0.06%)
Lipella Pharmaceuticals Inc. (LIPO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.4800 |
| Open | 2.4400 |
| Bid | 2.6700 x 900 |
| Ask | 2.7800 x 800 |
| Day's Range | 2.4101 - 2.8100 |
| 52 Week Range | 2.3100 - 7.7200 |
| Volume | |
| Avg. Volume | 949,033 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10
Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for whi
- PR Newswire
Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced that Dr. Jonathan Kaufman, Co-Founder, Chairman, and CEO will be presenting at Biotech Showcase™ 2023. The Biotech Showcase Conference is taking place in San Francisco in parallel to the J.P. Morgan (JPM) 41s
- PR Newswire
Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million
Lipella Pharmaceuticals Inc. ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications, today announced the closing of its initial public offering of 1,217,391 shares of its common stock at a price to the public of $5.75 per share. The gross proceeds from the offering to Lipella, before deducting the underwriting discounts an
